Unilever will not raise rejected 50 bln pound bid for GSK consumer arm


GSK has rejected three bids from Unilever for its consumer arm, which is home to brands such as Sensodyne toothpaste, Emergen-C vitamin supplement and Panadol painkiller, saying the bids "fundamentally undervalued" the business and its prospects. It has said it would stick to its plan to separately list the business in mid-2022 and issued improved financial assumptions for the unit.

Unilever PLC on Wednesday effectively abandoned its plans to buy GlaxoSmithKline's consumer healthcare business, saying that it would not raise its 50 billion pound ($68 billion) offer that GSK previously rejected.

U.S.-listed shares of Unilever rose 10.1% on the news, while GSK's fell 2.8%. The two stocks also trade on the FTSE, where the day's trading had closed.

Subscribe or renew your subscriptions to win prizes worth up to RM68,000!

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

Malton’s net profit surges 73%
Sarawak Oil Palms net profit up 30% in 3Q24
Strong ops performance lifts Axiata’s net profit
Philippines back to fiscal surplus in October
Singapore companies’ debt levels low
Direct Line rejects US$4.2bil takeover offer
TNB 3Q24 net profit soars 85% year-on-year
Capital A records net profit of RM1.64bil for 3Q24
FGV continues to improve palm oil productivity
Dnex actively pursuing more producing assets

Others Also Read